Immunomodulation and immunodeficiency

Veterinary Dermatology

Volumn 15, Issue 2, 2004, Pages 115-126

  Foster, Aiden P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cat; Dog; Immunodeficiency; Immunomodulation; Interferon; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERFERON OMEGA; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; CAT DISEASE; CHILL; CLINICAL TRIAL; DOG DISEASE; DRUG EFFECT; DRUG EFFICACY; EOSINOPHILIC GRANULOMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOMODULATION; LYMPHOCYTE; MYALGIA; NAUSEA; NEUTROPHIL; NONHUMAN; PAPILLOMATOSIS; PATHOGENESIS; PYODERMA; RETROVIRUS INFECTION; REVIEW; SIDE EFFECT; SKIN DISEASE; VETERINARY MEDICINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERONS; SEVERE COMBINED IMMUNODEFICIENCY; SKIN DISEASES;

CANIS FAMILIARIS; FELIDAE; FELIS CATUS; UNIDENTIFIED RETROVIRUS;

EID: 1842633767     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2004.00363.x     Document Type: Review

References (116)

1. Marsella, R., Olivry, T. Animal models of atopic dermatitis. Clinics in Dermatology 2003; 21: 122-33.
2. Olivry, T., Chan, L.S. Autoimmune blistering dermatoses in domestic animals. Clinics in Dermatology 2001; 19: 750-60.
3. Robinson, A., Sparkes, A.H., Day, M.J. Local cell recruitment and cytokine production following intradermal injection with Microsporum canis antigen in cats. In: Thoday, K.L., Foil, C.S., Bond, R. Advances in Veterinary Dermatology, Vol. 4. Oxford: Blackwell Science, 2002: 100-8.
4. Affolter, V.K., Moore, P.F. Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. American Journal of Dermatopathology 2000; 22: 40-8.
5. Nicholls, P.K., Stanely, M.A. The immunology of animal papillomaviruses. Veterinary Immunology and Immunopathology 2000; 73: 101-27.
6. Abbas, A.K., Lichtman, A.H. Cellular and Molecular Immunology, 5th edn. Philadelphia: W. B. Saunders, 2003: 453-76.
7. Janeway, C.A., Travers, P., Walport, M. et al. Immunobiology: The Immune System in Health and Disease, 5th edn. New York: Garland, 2001: 425-69.
8. Weller, I. Secondary Immunodeficiency. In: Roitt, I.M., Brostoff, J., Male, D.K., eds. Immunology, 6th edn. Edinburgh: Mosby-Year Book, 2001: 313-22.
9. Tizard, I.R. Veterinary Immunology: An Introduction, 6th edn. London: W. B. Saunders, 2000: 398-425.
10. Felsburg, P.J. Overview of the immune system and immunodeficiency diseases. Veterinary Clinics of North America: Small Animal Practice 1994; 24: 629-53.
11. Pedersen, N.C. A review of immunologic diseases of the dog. Veterinary Immunology and Immunopathology 1999; 69: 251-342.
12. Giger, U., Greene, C.E. Immunodeficiencies and infectious disease. In: Greene, C.E., ed. Infectious Diseases of the Dog and Cat. Philadelphia: WB. Saunders, 1998: 683-93.
13. Atherton, D.J. The neonate. In: Champion, R.H., Burton, J.L., Ebling, F.J.G., eds. Rook Wilson Ebling Textbook of Dermatology, 5th edn. Oxford: Blackwell Scientific, 1992: 381-443.
14. Campbell, K.L., Felsburg, P.J. IgA deficiency and skin disorders. In: Kirk, R.W, Bonagura, J.D., eds. Current Veterinary Therapy XI. Small Animal Practice. Philadelphia: WB. Saunders, 1992: 528-32.
15. DeBoer, D.J. Recognition and evaluation of the immunocompromised patient: bursting the bubble. Proceedings of the ESVD/ECVD Annual Congress, Copenhagen 2001: 125-8.
16. Thoday, K.L. Serum immunoglobulin concentrations in canine scabies. In: Ihrke, P.J., Mason, I.S., White, S.D., eds. Advances in Veterinary Dermatology, Vol. 2. Oxford: Pergamon Press, 1993: 211-27.
17. Studdert, V.P., Phillips, W.A., Studdert, M.J. et al. Recurrent and persistent infections in related Weimaraner dogs. Australian Veterinary Journal 1984; 61: 261-3.
18. Day, M.J., Power, C., Oleshko, J. et al. Low serum immunoglobulin concentrations in related Weimaraner dogs. Journal of Small Animal Practice 1997; 38: 311-15.
19. Moroff, S.D., Hurvitz, A.I., Peterson, M.E. et al. IgA deficiency in shar-pei dogs. Veterinary Immunology and Immunopathology 1986; 13: 181-8.
20. Miller, W.H., Wellington, J.R., Scott, D.W. Dermatologie disorders of Chinese shar-peis: 58 cases (1981-1989). Journal of the American Veterinary Medical Association 1992; 200: 986-90.
21. Rivas, A.L., Tintle, L., Argentieri, D. et al. A primary immunodeficiency syndrome in Shar-pei dogs. Clinical Immunology and Immunopathology 1995; 74: 243-51.
22. Felsburg, P.J., Glickman, L.T., Jezyk, P.F. Selective IgA deficiency in the dog. Clinical Immunology and Immunopathology 1985; 36: 297-305.
23. Day, M.J., Penhale, W.J. Serum immunoglobulin A concentrations in normal and diseased dogs. Research in Veterinary Science 1988; 45: 360-3.
24. Nuttall, T.J., Pemberton, A.D., Lamb, J.R. et al. Peripheral blood mononuclear cell responses to major and minor Dermatophagoides allergens in canine atopic dermatitis. Veterinary Immunology and Immunopathology 2002; 84: 143-50.
25. Bond, R., Elwood, C., Littler, R.M. et al. Humoral and cell-mediated responses to Malassezia pachydermatis in healthy dogs and dogs with Malassezia dermatitis. Veterinary Record 1998; 143: 381-4.
26. Martinez-Moreno, A., Moreno, T., Martinez-Moreno, F.J. et al. Humoral and cell-mediated immunity in natural and experimental canine Leishmaniasis. Veterinary Immunology and Immunopathology 1995; 48: 209-20.
27. McEwan, N.A., McNeil, P.E., Thompson, H. et al. Diagnostic features, confirmation and disease progression in 28 cases of lethal acrodermatitis of bull terriers. Journal of Small Animal Practice 2000; 41: 501-7.
28. Couto, C.G., Krakowka, S., Johnson, G. et al. In vitro immunologic features of Weimaraner dogs with neutrophil abnormalities and recurrent infections. Veterinary Immunology and Immunopathology 1989; 23: 103-12.
29. Giger, U., Boxer, L.A., Simpson, P.J. et al. Deficiency of leukocyte surface glycoproteins Mo1, LFA-1 and Leu M5 in a dog with recurrent bacterial infections: an animal model. Blood 1987; 69: 1622-30.
30. Trowald-Wigh, G, Håkansson, L., Johannisson, A. et al. Leucocyte adhesion protein deficiency in Irish setter dogs. Veterinary Immunology and Immunopathology 1992; 32: 261-80.
31. Renshaw, H.W., Chatburn, C., Bryan, G.M. et al. Canine granulocytopathy syndrome: neutrophil dysfunction in a dog with recurrent infections. Journal of the American Veterinary Medical Association 1975; 166: 443-7.
32. Lund, J.E., Padgett, G.A., Ott, R.L. Cyclic neutropenia in grey collie dogs. Blood 1967; 29: 452-61.
33. Casal, M.L., Straumann, U., Sigg, C. et al. Congenital hypotrichosis with thymic aplasia in nine Birmese kittens. Journal of the American Animal Hospital Association 1994; 30: 600-2.
34. Kramer, J.W., Davis, W.C., Prieur, D.J. The Chediak-Higashi syndrome of cats. Laboratory Investigation, 1977; 36: 554-62.
35. Church, A.C. X-Linked severe combined immunodeficiency. Hospital Medicine 2002; 63: 676-80.
36. Hartnett, B.J., Somberg, R.L., Krakowka, B.J. B-Cell function in canine X-linked severe combined immunodeficiency. Veterinary Immunology and Immunodeficiency 2000; 75: 121-34.
37. Pullen, R.P., Somberg, R.L., Felsburg, P.J. et al. X-Linked severe combined immunodeficiency in a family of Cardigan Welsh corgis. Journal of the American Animal Hospital Association 1997; 33: 494-9.
38. Felsburg, P.J., Hartnett, B.J., Henthorn, P.S. et al. Canine X-linked severe combined immunodeficiency. Veterinary Immunology and Immunopathology 1999; 69: 127-35.
39. Medleau, L. Recently described feline dermatoses. Veterinary Clinics of North America: Small Animal Practice 1990; 20: 1615-32.
40. Guaguère, E., Declercq, J. Viral dermatoses. In: Guaguère, E., Prélaud, P., eds. A Practical Guide to Feline Dermatology. Paris: Merial, 1999; 7: 1-11.
41. Yamamoto, J.K., Hansen, H., Ho, E.W. et al. Epidemiologie and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. Journal of the American Veterinary Medical Association 1989; 194: 213-20.
42. Shaw, S.E., Robertson, I.D., Robinson, W.F. et al. Feline immunodeficiency virus - disease associations. Australian Veterinary Practitioner 1990; 20: 194-8.
43. Sierra, P., Guillot, J., Jacob, H. et al. Fungal flora on cutaneous and mucosal surfaces of cats infected with feline immunodeficiency virus or feline leukaemia virus. American Journal of Veterinary Research; 61: 158-61.
44. Mancianti, F., Giannelli, C., Bendinelli, M. et al. Mycological findings in feline immunodeficiency virus-infected cats. Journal of Medical and Veterinary Mycology 1992; 30: 257-9.
45. Mignon, B.R., Losson, B.J. Prevalence and characterisation of Microsporum canis carriage in cats. Journal of Medical and Veterinary Mycology 1997; 35: 249-56.
46. Bennett, M., McCracken, C., Lutz, H. et al. Prevalence of antibody to feline immunodeficiency virus in some cat populations. Veterinary Record 1989; 124: 397-8.
47. Bennett, M., Gaskell, D., Baxby, D. et al. Feline cow-pox virus infection. Journal of Small Animal Practice 1990; 31: 167-73.
48. Theon, A.P. Intralesional and topical chemotherapy and immunotherapy. Veterinary Clinics of North America: Equine Practice 1998; 14: 659-71.
49. Knottenbelt, D.C., Kelly, D.F. The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999. Veterinary Ophthalmology 2000; 3: 169-91.
50. Rush, B.R., Flaminio, M.J.B.F. Immunomodulation in horses. Veterinary Clinics of North America: Equine Practice 2000; 16: 183-97.
51. Matricardi, P.M., Bjorksten, B., Bonini, S. et al. Microbial products in allergy prevention and therapy. Allergy 2003; 58: 461-71.
52. Camporota, L., Corkhill, A., Long, H., et al. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. European Respiratory Journal 2003; 21: 287-93.
53. Erb, K.J., Wohlleben, G. Novel vaccines protecting against the development of allergic disorders: a double-edged sword? Current Opinion in Immunology 2002; 14: 633-43.
54. Lewis, D. B. Allergy immunotherapy and inhibition of Th2 immune responses: a sufficient strategy? Current Opinion in Immunology 2002; 14: 644-51.
55. Williams, J.D.L., Griffiths, C.E.M. Cytokine blocking agents in dermatology. Clinical and Experimental Dermatology 2002; 27: 585-90.
56. Robinet, E., Stamm, C., Nicholas, J-F. et al. CD4 monoclonal antibody administration in atopic dermatitis. Journal of the American Academy of Dermatology 1997; 36: 582-8.
57. Mrowietz, U. Treatment targeted to cell surface epitopes. Clinical and Experimental Dermatology 2002; 27: 591-6.
58. Asadullah, K., Sterry, W., Trefzer, U. Cytokines: interleukin and interferon therapy in dermatology. Clinical and Experimental Dermatology 2002; 27: 578-84.
59. Wikel, S. K., Alarcon-Chaidez, F.J. Progress toward molecular characterization of ectoparasite modulation of host immunity. Veterinary Parasitology 2001; 101: 275-87.
60. Willadsen, P. The molecular revolution in the development of vaccines against ectoparasites. Veterinary Parasitology 2001; 101: 353-67.
61. Trimnell, A.R., Hails, R.S., Nuttall, P.A. Dual action ectoparasite vaccine targeting 'exposed' and 'concealed' antigens. Vaccine 2002; 20: 3560-8.
62. Parmiani, G., Castelli, C., Dalerba, P. et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? 2002; 94: 805-18.
63. Nestle, F.O. Vaccines and melanoma. Clinical and Experimental Dermatology 2002; 27: 597-601.
64. Maeda, S., Okayama, T., Omori, K. et al. Expression of CC chemokine receptor 4 (CCR4) mRNA in canine atopic skin lesion. Veterinary Immunology and Immunopathology 2002; 90: 145-54.
65. Nickel, R., Beck, L.A., Schleimer, R.P. Chemokines and allergic disease. Journal of Allergy and Clinical Immunology 1999; 104: 723-42.
66. Katze, M.G, He, Y., Gale, M. Viruses and interferon: a fight for supremacy. Nature Reviews Immunology 2002; 2: 675-87.
67. Kruth, S.A. Biological response modifiers: interferons, interleukins, recombinant products, liposomal products. Veterinary Clinics of North America: Small Animal Practice 1998; 28: 269-95.
68. Leonard, W.J., Lin, J.-X. Cytokine receptor signalling pathways. Journal of Allergy and Clinical Immunology 2000; 105: 877-88.
69. Kotenko, S.V., Gallagher, G., Baurin, V.V. et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunology 2003; 4: 69-77.
70. Sheppard, P., Kindsvogel, W., Xu, W.F. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology 2003; 4: 63-8.
71. Hanifin, J.M., Schenider, L.C., Leung, D.Y.M. et al. Recombinant interferon gamma interferon gamma therapy for atopic dermatitis. Journal of the American Academy of Dermatology 1993; 28: 189-97.
72. Sidbury, R., Hanifin, J.M. Systemic therapy of atopic dermatitis. Clinical and Experimental Dermatology 2000; 25: 559-66.
73. Luger, T.A., Schwarz, T. Therapeutic use of cytokines in dermatology. Journal of the American Academy of Dermatology 1991; 24: 915-26.
74. Helton-Rhodes, K. Feline immunomodulators. In: Bonagura, J.D., ed. Current Veterinary Therapy XII. Philadelphia: WB. Saunders, 1995: 581-4.
75. Scott, D.W., Miller, W.H., Griffin, C.E. Muller and Kirk's Small Animal Dermatology, 6th edn. Philadelphia: WB. Saunders, 2001: 252-3.
76. Schwassman, M. Uses of interferon. Dermatology Dialogue, (AAVD Newsletter) Winter 1999: 9.
77. Martin, V., Najbar, W., Gueguen, S. et al. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Veterinary Microbiology 2002; 89: 115-27.
78. White, S.D. Nonsteroidal immunosuppressive therapy. In: Bonagura, J.D., ed. Kirk's Current Veterinary Therapy XIII. Small Animal Practice. Philadelphia: W.B. Saunders, 2000: 536-8.
79. Kazatchkine, M.D., Kaveri, S.V. Immunology of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine 2001; 345: 747-55.
80. Gelfand, E.W. Antibody-directed therapy. Past, present, and future. Journal of Allergy and Clinical Immunology 2001; 108: S111-16.
81. Sacher, R.A., IVIG Advisory Panel. Intravenous immunoglobulin consensus statement. Journal of Allergy and Clinical Immunology 2001; 108: S139-46.
82. Jolles, S., Hughes, J., Rustin, M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. British Journal of Dermatology 2000; 142: 551-4.
83. Ott, V.L., Fong, D.C., Cambier, J.C. FcγRIIB as a potential molecular target for intravenous gamma globulin therapy. Journal of Allergy and Clinical Immunology 2001; 108: S95-8.
84. Scott-Montcrieff, J.C.R., Reagan, W.J., Snyder, P.W. et al. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. Journal of the American Veterinary Medical Association 1997; 210: 1623-7.
85. Byrne, K.P., Giger, U. Use of human immunoglobulin for the treatment of severe erythema multiforme in a cat. Journal of the American Veterinary Medical Association 2002; 220: 197-201.
86. Rosser, E.J. German shepherd dog pyoderma. A prospective study of 12 dogs. Journal of the American Animal Hospital Association 1997; 33: 355-63.
87. Wisselink, M.A., van Kessel, K.P.M., Willemse, T. Leukocyte mobilization to skin lesions, determination of cell surface receptors (CD11b/CD18) and phagocytic capacities of neutrophils in dogs with chronic deep pyoderma. Veterinary Immunology and Immunodeficiency 1997; 57: 179-86.
88. Chammas, P.P.C., Hagiwara, M.K. Evaluation of neutrophilic function (chemotaxis, phagocytosis and microbicidal activity) in healthy dogs and in dogs suffering from recurrent deep pyoderma. Veterinary Immunology and Immunodeficiency 1998; 64: 123-31.
89. Miller, W.H. Deep pyoderma in two German shepherd dogs associated with a cell-mediated immunodeficiency. Journal of the American Animal Hospital Association 1991; 27: 513-17.
90. Chabanne, L., Marchal, T., Denerolle, P. et al. Lymphocyte subset abnormalities in German shepherd dog pyoderma (GSP). Veterinary Immunology and Immunodeficiency 1995; 49: 189-98.
91. Denerolle, P., Bourdoiseau, G., Magnol, J.-P. et al. German shepherd dog pyoderma. A prospective study of 23 cases. Veterinary Dermatology 1998; 9: 243-8.
92. Day, M.J., Mazza, G. Tissue immunoglobulin-G subclasses observed in immune-mediated dermatopathy, deep pyoderma and hypersensitivity dermatitis in dogs. Research in Veterinary Science 1995; 58: 82-9.
93. Morales, C.A., Schultz, K.T., DeBoer, D.J. Antistaphylococcal antibodies in dogs with recurrent staphylococcal pyoderma. Veterinary Immunology and Immunopathology 1994; 42: 137-47.
94. Pukay, B.P. Treatment of canine bacterial hypersensitivity by hyposensitisation with Staphylococcus aureus bacterin-toxoid. Journal of the American Animal Hospital Association 1985; 21: 479-83.
95. 5. Scott, D.W. Immunologic skin disorders in the dog and cat. Veterinary Clinics of North America 1978; 8: 641-63.
96. Halliwell, R.E.W. Levels of IgE and IgG antibody to staphylococcal antigens in normal dogs and in dogs with recurrent pyoderma. In: Proceedings of the Annual Members' Meeting of AAVD and ACVD, Phoenix, AZ, 1987:5.
97. Shearer, D.H., Day, M.J. Aspects of the humoral immune response to Staphylococcus intermedius in dogs with superficial pyoderma, deep pyoderma and anal furunculosis. Veterinary Immunology and Immunopathology 1997; 58: 107-20.
98. Shearer, D.H., Day, M.J. An investigation of phagocytosis and intracellular killing of Staphylococcus intermedius by canine neutrophils in vitro. Veterinary Immunology and Immunopathology 1997; 58: 219-30.
99. Noble, W.C., Lloyd, D.H. Pathogenesis and management of wound infections in domestic animals. Veterinary Dermatology 1997; 8: 243-8.
100. Almazan, J. Fuente de al, R., Gomez, L.E. et al. Enterotoxin production by strains of Staphylococcus intermedius and Staphylococcus aureus isolated from dog infections. Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene Series A 1987; 264: 29-32.
101. Fukuda, S., Tokuno, H., Ogawa, H. et al. Enterotoxigenicity of Staphylococcus intermedius strains isolated from dogs. Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene Series A 1984; 258: 360-7.
102. Edwards, V.M., Deringer, J.R., Callantine, S.D. et al. Characterization of the canine type C enterotoxin produced by Staphylococcus intermedius pyoderma isolates. Infection and Immunity 1997; 65: 2346-52.
103. Burkett, G., Frank, L.A. Comparison of production of Staphylococcus intermedius exotoxin among clinically normal dogs, atopic dogs with recurrent pyoderma and dogs with a single episode of pyoderma. Journal of the American Veterinary Medical Association 1998; 213: 232-4.
104. Allaker, R.P., Lamport, A.I., Lloyd, D.H. et al. Production of 'virulence factors' by Staphylococcus intermedius isolates from cases of canine pyoderma and healthy carriers. Microbial Ecology in Health and Disease 1991; 4: 169-73.
105. DeBoer, D.J. Immunomodulatory effects of staphylococcal antigen and antigen-antibody complexes on canine mononuclear leukocytes. American Journal of Veterinary Research 1994; 55: 1690-6.
106. Hendricks, A., Schuberth, H.-J., Schueler, K. et al. Frequency of superantigen-producing Staphylococcus intermedius isolates from canine pyoderma and proliferation-inducing potential of superantigens in dogs. Research in Veterinary Science 2003; 73: 273-7.
107. Leung, D.Y.M., Hauk, P., Strickland, I. et al. The role of superantigens in human diseases. Therapeutic implications for the treatment of skin diseases. British Journal of Dermatology 1998; 139: 17-29.
108. Tipold, A., Somberg, R., Henthorn, P. et al. Restriction fragment length polymorphism of the T-cell receptor beta-chain gene in dogs. Veterinary Immunology and Immunopathology 1996; 51: 225-33.
109. Curtis, C.F. Control of recurrent superficial pyoderma in the dog: part 1 - the value of immunomodulatory drugs and bacterins. CPD Veterinary Medicine 2000; 2: 95-7.
110. Hendricks, A. Staphylococci and vaccines - past, present and future. Proceedings of the British Veterinary Dermatology Study Group - Spring Meeting, Birmingham 2001: 35-43.
111. DeBoer, D.J. Management of chronic and recurrent pyoderma in the dog. In: Bonagura, J.D., ed. Kirk's Current Veterinary Therapy XII. Small Animal Practice. Philadelphia: W.B. Saunders, 1995: 611-17.
112. DeBoer, D.J., Schultz, K.T., Thomas, C.B. et al. Clinical and immunological responses of dogs with recurrent pyoderma to injections of Staphylococcus phage lysate. In: Von Tscharner, C., Halliwell, R.E.W., eds. Advances in Veterinary Dermatology, Vol. 1. London: Baillière Tindall, 1990: 335-46.
113. Werling, D., Jungi, T.W. TOLL-like receptors linking innate and adaptive immune responses. Veterinary Immunology and Immunopathology 2003; 91: 1-12.
114. Becker, A.M., Janik, T.A., Smith, E.K. et al. Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma. Journal of Veterinary International Medicine 1989; 3: 26-30.
115. DeBoer, D.J., Moriello, K.A., Thomas, C.B. et al. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs. American Journal of Veterinary Research 1990; 51: 636-9.
116. Curtis, C.F., Lamport, A.I., Lloyd, D.H. Blinded, controlled study to investigate the efficacy of a staphylococcal autogenous bacterin for the control of canine idiopathic recurrent pyoderma. Proceedings of the 16th Annual Congress of ESVD-ECVD, Helsinki, 1999: 148.